Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 184B5 | NM | Basal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5897.074 | 0.1006 | -0.6663 | 1.2824 | |
| 184B5 | NM | Basal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5897.074 | 0.1006 | -0.6663 | 1.2824 | |
| 184B5 | NM | Basal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5897.074 | 0.0631 | -0.7681 | 1.2824 | |
| 184B5 | NM | Basal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5897.074 | 0.0631 | -0.7681 | 1.2824 | |
| 184B5 | NM | Basal | Bortezomib | Proteasome | Proteasome | 167 | uM | 5897.074 | 0.0539 | -0.7949 | 1.2824 | |
| 184B5 | NM | Basal | Bortezomib | Proteasome | Proteasome | 167 | uM | 5897.074 | 0.0539 | -0.7949 | 1.2824 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14779.203 | 0.9733 | 0.9727 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14779.203 | 0.9733 | 0.9727 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14779.203 | 1.0164 | 1.0166 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14779.203 | 1.0164 | 1.0166 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14779.203 | 0.9905 | 0.9903 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14779.203 | 0.9905 | 0.9903 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14779.203 | 0.9664 | 0.9656 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14779.203 | 0.9664 | 0.9656 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14779.203 | 0.9301 | 0.9278 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14779.203 | 0.9301 | 0.9278 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14779.203 | 0.7956 | 0.7808 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14779.203 | 0.7956 | 0.7808 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14779.203 | 0.5045 | 0.4130 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14779.203 | 0.5045 | 0.4130 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14779.203 | 0.0236 | -0.7015 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14779.203 | 0.0236 | -0.7015 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14779.203 | 0.0184 | -0.7373 | 1.9695 | |
| 21MT-1 | HER2amp | - | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14779.203 | 0.0184 | -0.7373 | 1.9695 | |
| 21NT | HER2amp | - | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14783.203 | 1.0462 | 1.0489 | 1.8667 |